If developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) were a poker game, you could say Novo Nordisk (NASDAQ Copenhagen: NOVO-B) saw a competitor’s bet and raised the stakes ...

Metabolic-associated steatohepatitis (MASH) happens when excess fat in the liver causes inflammation and scarring, or fibrosis. The condition is serious, and when left untreated it can lead to ...

The second edition of the Mash Ball, held at The St. Regis Mumbai on October 5, 2025, unfolded as a glittering celebration of art, fashion, and social impact. Conceptualised by Shalini Passi, founder ...

Note: The U.S. Food and Drug Administration (FDA) doesn’t approve supplements for safety or effectiveness. Always talk with your healthcare professional about whether a supplement fits your health ...

Forbes contributors publish independent expert analyses and insights. David Thomas Tao is an NYC-based spirits writer and media producer.

Jack Daniel’s Distillery Series is a collection of whiskeys that highlights the use of different mashbills, secondary maturations, and production methods, and is only available in limited numbers in ...

Hall of Fame quarterback Dan Marino recently revealed that he was diagnosed with metabolic dysfunction-associated steatohepatitis, or MASH. The Miami Dolphins legend said the discovery came years ago ...

There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the ...

Roche dived into the metabolic dysfunction-associated steatohepatitis (MASH) space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate for the fatty liver disease. At ...

NEW YORK, NEW YORK - JUNE 21: Dan Marino speaks onstage at Fanatics Fest NYC 2025 at Javits Center on June 21, 2025 in New York City. (Photo by Slaven Vlasic/Getty Images) To say that Dan Marino has ...

Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an ...